Will be interesting to see what kind of deal Inven
Post# of 148165
more recent attempts to secure cash through “the issuance of debt, equity and other instruments” have been unsuccessful, the company said.
A long-term solution could range “from partnerships to outright sale,” Stifel analysts said in a Sunday note. But finding a partner interested in MASH could be challenging given the recent “downstream evidence” of Eli Lilly’s dual GLP-1/GIP receptor agonist tirzepatide achieving MASH resolution with fibrosis data, they added.
https://endpts.com/inventiva-ramps-up-search-...-in-weeks/